Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature. [electronic resource]
Producer: 20180723Description: 6430-6440 p. digitalISSN:- 1557-3265
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Azacitidine -- administration & dosage
- Combined Modality Therapy
- Cyclin-Dependent Kinase Inhibitor p16
- Cyclin-Dependent Kinase Inhibitor p18 -- genetics
- Disease-Free Survival
- Drug Administration Schedule
- Female
- Histone Deacetylase Inhibitors -- administration & dosage
- Humans
- Hydroxamic Acids -- administration & dosage
- Isocitrate Dehydrogenase -- genetics
- Leukemia, Myeloid, Acute -- drug therapy
- Male
- Middle Aged
- Mutation
- Treatment Outcome
- Tumor Suppressor Protein p53 -- genetics
- Vorinostat
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.